LDR wins FDA clearance for ROI-A ALIF device
Previously cleared in April 2008 as a partial vertebral body replacement, the ROI-A system incorporates the innovative VerteBRIDGE screwless plating technology. According to LDR, the ROI-A anterior lumbar
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.